Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Flotillin-1 is a membrane-associated protein and member of the SPFH (stomatin, prohibitin, flotillin, HflK/C) superfamily, encoded by the FLOT1 gene on chromosome 6[1][2][4]. It is widely expressed in human tissues and primarily localizes to the cytoplasmic side of the plasma membrane, as well as to certain intracellular compartments including the Golgi, lysosomes, endosomes, and nuclei[1][4]. Flotillin-1 forms hetero-oligomeric complexes with flotillin-2, enhancing membrane raft stabilization and organization[3][4]. As a scaffolding protein, flotillin-1 is central to the formation and functional organization of lipid rafts—specialized membrane microdomains involved in cell signaling, receptor trafficking, and endocytosis (including clathrin-independent pathways)[1][2][4]. It facilitates the endocytosis and membrane cycling of several key transporters and receptors, such as the dopamine transporter, IGF-1 receptor, and muscarinic M3 receptor[1]. Flotillin-1 is also an established marker for exosomes and serves various roles in membrane trafficking and signal transduction[1][4]. Post-translational modifications, such as S-palmitoylation, sumoylation, and phosphorylation, regulate flotillin-1’s membrane association, subcellular localization, and function[1][2][4]. Aberrant flotillin-1 expression or modification is linked to pathological processes, including tumor development (where it can function as either oncogene or tumor suppressor context-dependently), neurodegenerative diseases like Parkinson's disease, infections, cardiovascular pathology, metabolic disorders, and more[1][4]. Although flotillin-1 is not a conventional therapeutic target (such as a receptor, ion channel, enzyme, or transporter), its implications in disease progression and as a biomarker have been increasingly recognized, particularly in oncology and neurological research[1][4]. No direct drugs targeting flotillin-1 are currently established, but its modulation impacts the efficacy or localization of several druggable targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Flotillin-1 (FLOT1).